MDRNA, Inc. Receives NASDAQ Notification

BOTHELL, WA, Nov 12 (MARKET WIRE) --
MDRNA, Inc. (NASDAQ: MRNA) announced today that on November 6, 2009 it
received a letter from The NASDAQ Stock Market, Inc. notifying the
Company that, for ten consecutive business days, based on the Company's
Market Value of Listed Securities (MVLS), it did not comply with the $50
million minimum MVLS for continued listing on The NASDAQ Global Market
set forth in NASDAQ Marketplace Rule 5450(b)(3)(A). The Company has a
grace period of 90 calendar days (until February 4, 2010) in order to
regain compliance, which can be achieved if the Company's MVLS closes at
$50 million or more for a minimum of ten consecutive business days during
this time. MDRNA will continue to be listed on the NASDAQ Global Market
during this period.

"We believe we are taking all necessary steps to enhance shareholder value
and regain compliance with NASDAQ's listing requirements," stated J.
Michael French, President and Chief Executive Officer of MDRNA. "Based
upon the continued advancement of both our science and oncology programs
and our on-going business development efforts, we are confident that we
will be able to meet the Nasdaq Global Markets listing requirements
within the 90 day grace period."

About MDRNA, Inc.

MDRNA is a biotechnology company focused on the development and
commercialization of therapeutic products based on RNA interference
(RNAi). Our goal is to improve human health through the development of
RNAi-based compounds and drug delivery technologies that together provide
superior therapeutic options for patients. Over the past decade, we have
developed substantial capabilities in molecular biology, cellular
biology, lipid chemistry, peptide chemistry, pharmacology and
bioinformatics, which we are applying to a wide range of RNAi
technologies and delivery approaches. These capabilities plus the
in-licensing of key RNAi-related intellectual property have rapidly
enabled us to become a leading RNAi-based therapeutics company with a
pre-clinical pipeline in oncology. Through our capabilities, expertise
and know-how, we are incorporating multiple RNAi technologies as well as
peptide- and lipid-based delivery approaches into a single integrated
drug discovery platform that will be the engine for our clinical pipeline
as well as a versatile platform for establishing broad therapeutic
partnerships with biotechnology and pharmaceutical companies. We are also
investing in new technologies that we expect to lead to safer and more
effective RNAi-based therapeutics while aggressively building upon our
broad and extensive intellectual property estate. By combining broad
expertise in siRNA science with proven delivery platforms and a strong IP
position, MDRNA is well positioned as a leading RNAi-based drug discovery
and development company. Additional information about MDRNA, Inc. is
available at http://www.mdrnainc.com.

MDRNA Forward-Looking Statements

Statements made in this news release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results
to differ materially from those projected or suggested. Factors that could
cause actual results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of MDRNA to
obtain additional funding; (ii) the ability of MDRNA to attract and/or
maintain manufacturing, research, development and commercialization
partners; (iii) the ability of MDRNA and/or a partner to successfully
complete product research and development, including preclinical and
clinical studies and commercialization; (iv) the ability of MDRNA and/or a
partner to obtain required governmental approvals; and (v) the ability of
MDRNA and/or a partner to develop and commercialize products that can
compete favorably with those of competitors. Additional factors that could
cause actual results to differ materially from those projected or
suggested in any forward-looking statements are contained in MDRNA's most
recent periodic reports on Form 10-K and Form 10-Q that are filed with the
Securities and Exchange Commission. MDRNA assumes no obligation to update
and supplement forward-looking statements because of subsequent events.

Contacts:

MDRNA, Inc.:
Peter Garcia
Chief Financial Officer
(425) 908-3603
pgarcia@mdrnainc.com

Westwicke Partners (Investors):
Stefan Loren, Ph.D.
(443) 213-0507
sloren@westwicke.com
John Woolford
(443) 213-0506
john.woolford@westwicke.com

McKinney|Chicago (Media):
Alan Zachary
(312) 944-6784 x 316 or
(708) 707-6834
azachary@mckinneychicago.com

Copyright 2009, Market Wire, All rights reserved.

-0-